Potentially inappropriate prescribing of DOACs to people with mechanical heart valves: a federated analysis of 57.9 million patients’ primary care records in situ using OpenSAFELY
The OpenSAFELY Collaborative None., Fisher L., Speed V., Curtis H., Rentsch C., Wong AYS., Schultze A., Massey J., Inglesby P., Morton C., Wood M., Walker A., Morley J., Mehrkar A., Bacon S., Hickman G., Bates C., Croker R., Evans D., Ward T., Cockburn J., Davy S., Bhaskaran K., Smith B., Williamson E., Hulme W., Green A., Eggo R., Forbes H., Tazare J., Parry J., Hester F., Harper S., Meadows J., O’Hanlon S., Eavis A., Jarvis R., Avramov D., Griffiths P., Fowles A., Parkes N., Douglas I., Evans SJW., Tomlinson L., MacKenna B., Smeeth L., Goldacre B.
National guidance was issued during the COVID-19 pandemic to switch patients on warfarin to direct oral anticoagulants (DOACs) where appropriate as these require less frequent blood testing. DOACs are not recommended for patients with mechanical heart valves. We conducted a retrospective cohort study of DOAC prescribing in people with a record of a mechanical heart valve between September 2019 and May 2021, and describe the characteristics of this population. We identified 15,457 individuals with a mechanical heart valve recorded in their records, of whom 1058 (6.8%) had been prescribed a DOAC during the study period. 767 individuals with a record of a mechanical heart valve were currently prescribed a DOAC as of May 31st 2021. This is suggestive of inappropriate prescribing of DOACs in individuals with mechanical heart valves. Direct alerts have been issued to clinicians through their EHR software informing the issue. We show that the OpenSAFELY platform can be used for rapid audit and feedback to mitigate the indirect health impacts of COVID-19 on the NHS. We will monitor changes in prescribing for this risk group over the following months.